

**Supplementary Table 5.** Demographics and clinicopathologic characteristics of patients between groups N0 + A + B and C

Characteristic	Group N0 + A + B	Group C	P-value
Age (yr)			0.567
≤60	55 (58.5)	25 (64.1)	
>60	39 (41.5)	14 (35.9)	
Sex			>0.999
Male	47 (50.0)	20 (51.3)	
Female	47 (50.0)	19 (48.7)	
Hemoglobin (g/L)			0.058
≤130	48 (51.1)	27 (69.2)	
>130	46 (48.9)	12 (30.8)	
Serum albumin (g/L)			0.116
≤35	7 (7.4)	7 (17.9)	
>35	87 (92.6)	32 (82.1)	
TBIL (μmol/L)			0.137
≤17.1	64 (68.1)	32 (82.1)	
>17.1	30 (31.9)	7 (17.9)	
ALT (U/L)			0.843
≤40	60 (63.8)	26 (66.7)	
>40	34 (36.2)	13 (33.3)	
γ-GT (U/L)			0.631
≤50	17 (18.1)	9 (23.1)	
>50	77 (81.9)	30 (76.9)	
PT (sec)			>0.999
≤14	91 (96.8)	38 (97.4)	
>14	3 (3.2)	1 (2.6)	
INR			0.448
≤1.15	89 (94.7)	35 (89.7)	
>1.15	5 (5.3)	4 (10.3)	
HBsAg			0.826
Negative	71 (75.5)	29 (74.4)	
Positive	22 (23.4)	10 (25.6)	
Missing	1 (1.1)	0 (0)	
CEA (μg/L)			0.248
≤5	59 (62.8)	20 (51.3)	
>5	35 (37.2)	19 (48.7)	
CA 125 (U/mL)			0.168
≤35	65 (69.1)	22 (56.4)	
>35	29 (30.9)	17 (43.6)	
CA 19-9 (U/mL)			>0.999
≤35	27 (28.7)	11 (28.2)	
>35	67 (71.3)	28 (71.8)	
Tumor number			0.819
1	68 (72.3)	29 (74.4)	
>1	19 (20.2)	9 (23.1)	
Missing	7 (7.5)	1 (2.5)	
Tumor size (cm)			0.030
≤5	42 (44.7)	10 (25.6)	
>5	45 (47.9)	28 (71.8)	
Missing	7 (7.4)	1 (2.6)	
Tumor type			>0.999
Non-mass-forming	9 (9.6)	4 (10.3)	
Mass-forming	85 (90.4)	35 (89.7)	
Surgical margin			0.478
R0	88 (93.6)	35 (89.7)	
R1	6 (6.4)	4 (10.3)	
No. of LNs harvested			0.345
<6	50 (53.2)	17 (43.6)	
≥6	44 (46.8)	22 (56.4)	

**Supplementary Table 5.** Continued

Characteristic	Group N0 + A + B	Group C	P-value
Vascular invasion			0.046
No	71 (75.5)	23 (59.0)	
Yes	18 (19.2)	14 (35.9)	
Missing	5 (5.3)	2 (5.1)	
Surgery time (min)			0.437
≤300	59 (62.8)	21 (53.8)	
>300	35 (37.2)	18 (46.2)	
Blood loss (mL)			0.129
≤300	53 (56.4)	16 (41.0)	
>300	41 (43.6)	23 (59.0)	
Blood transfusion			0.679
No	67 (71.3)	26 (66.7)	
Yes	27 (28.7)	13 (33.3)	
Postoperative hospital stay (day)			0.846
≤12	58 (61.7)	23 (59.0)	
>12	36 (38.3)	16 (41.0)	
Postoperative complication			0.483
No	74 (78.7)	33 (84.6)	
Yes	20 (21.3)	6 (15.4)	
Adjuvant treatment			0.723
No	86 (91.5)	37 (94.9)	
Yes	8 (8.5)	2 (5.1)	

Values are presented as number (%).

TBIL, total bilirubin; INR, international normalized ratio; LN, lymph node.